首页> 外文期刊>Advanced Science >Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs
【24h】

Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs

机译:外泌体-脂质体杂合纳米颗粒在MSC中提供CRISPR / Cas9系统

获取原文
           

摘要

Targeted delivery of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) system to the receptor cells is essential for in vivo gene editing. Exosomes are intensively studied as a promising targeted drug delivery carrier recently, while limited by their low efficiency in encapsulating of large nucleic acids. Here, a kind of hybrid exosomes with liposomes is developed via simple incubation. Different from the original exosomes, the resultant hybrid nanoparticles efficiently encapsulate large plasmids, including the CRISPR–Cas9 expression vectors, similarly as the liposomes. Moreover, the resultant hybrid nanoparticles can be endocytosed by and express the encapsulated genes in the mesenchymal stem cells (MSCs), which cannot be transfected by the liposome alone. Taken together, the exosome–liposome hybrid nanoparticles can deliver CRISPR–Cas9 system in MSCs and thus be promising in in vivo gene manipulation.
机译:将聚簇的规则间隔的短回文重复序列(CRISPR)/ CRISPR相关蛋白9(Cas9)系统靶向递送至受体细胞对于体内基因编辑至关重要。外来体最近被广泛研究为有前途的靶向药物递送载体,同时由于它们在封装大核酸中的低效率而受到限制。在这里,通过简单的温育发展了一种与脂质体混合的外泌体。与原始外泌体不同,所得杂化纳米颗粒与脂质体类似,有效地包裹了大质粒,包括CRISPR–Cas9表达载体。而且,所得的杂化纳米颗粒可以被间充质干细胞(MSC)内吞并在其内表达被包封的基因,而单独的脂质体不能对其进行转染。总而言之,外泌体-脂质体杂交纳米颗粒可以在MSC中提供CRISPR-Cas9系统,因此有望在体内基因操作中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号